Loading…
Fate Therapeutics, Inc. is projected to rise to $3.41 by 2027, a +44% move from its current price of $2.37. FATE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.22 | $2.37 | $2.53 | +0.09% |
| May 30 | $2.17 | $2.37 | $2.60 | +0.17% |
| May 31 | $2.13 | $2.38 | $2.66 | +0.26% |
| Jun 1 | $2.09 | $2.38 | $2.70 | +0.34% |
| Jun 2 | $2.06 | $2.38 | $2.75 | +0.43% |
| Jun 3 | $2.03 | $2.38 | $2.79 | +0.51% |
| Jun 4 | $2.01 | $2.38 | $2.83 | +0.60% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.01 | $2.38 | $2.83 | +0.60% |
| Week 2 | $1.89 | $2.40 | $3.05 | +1.20% |
| Week 3 | $1.80 | $2.41 | $3.24 | +1.81% |
| Week 4 | $1.73 | $2.43 | $3.41 | +2.42% |
| Week 5 | $1.67 | $2.44 | $3.57 | +3.04% |
| Week 6 | $1.62 | $2.46 | $3.73 | +3.66% |
| Week 7 | $1.58 | $2.47 | $3.88 | +4.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. Its CAR-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd.
for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors.
The company was incorporated in 2007 and is headquartered in San Diego, California.
Fate Therapeutics, Inc. (FATE) operates in the Healthcare sector as a clinical-stage biopharmaceutical company focused on programmed cellular immunotherapies.
The stock is currently trading at $2.25 with a market capitalization of $262.26M and is ranked 3638.
Forecasts indicate a path of rising average prices in the years ahead, with 2026 avg $2.25, 2027 avg $3.25, 2028 avg $4.16, 2029 avg $3.79, 2030 avg $3.78, and higher still in 2040 ($16.91) and 2050 ($34.59). The sentiment shifts to bullish in most future years, while 2026 is neutral.
A major floor 65.3% below — a decisive break under it would weaken the trend.
The nearest floor, 47.7% below — buyers have tended to step in here.
Price is pressing into resistance (2.5% away) — a breakout level to watch.
A major ceiling 35.2% above — clearing it would confirm fresh momentum.
Key FATE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FATE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.14 | Buy | $2.18 | Buy |
| MA 10 | $2.01 | Buy | $2.09 | Buy |
| MA 20 | $1.99 | Buy | $1.96 | Buy |
| MA 50 | $1.54 | Buy | $1.68 | Buy |
| MA 100 | $1.39 | Buy | $1.49 | Buy |
| MA 200 | $1.26 | Buy | $1.42 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.98 | Neutral |
| Stoch RSI (14) | 45.75 | Neutral |
| CCI (20) | 84.10 | Neutral |
| Williams %R (14) | -8.57 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -0.84 | Sell |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 91.43 | Sell |
| TRIX (15) | 1.62 | Buy |
| Awesome (5,34) | 0.42 | Buy |
| Ultimate (7,14,28) | 70.70 | Sell |
| Momentum (10) | 0.12 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 2.33 | Buy |
| ADX (14) | 23.05 | Buy |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is bullish.
RSI14 is 60, and the trend is supported by a 50-day simple moving average of $1.50 versus a 200-day simple moving average of $1.25, suggesting a constructive near-term trajectory.
Support is at $1.24 and resistance at $2.43, framing the near-term range. The 30-day price range spans from $1.47 to $3.44, indicating room for upside with some pullback potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.99 | $2.37 | $4.07 | 0% | Neutral | |
| $2.46 | $3.41 | $5.13 | +44% | Bullish | |
| $2.97 | $4.38 | $7.00 | +85% | Bullish | |
| $2.65 | $4.11 | $6.88 | +73% | Bullish | |
| $2.51 | $4.09 | $7.13 | +72% | Bullish | |
| $3.53 | $6.00 | $10.82 | +153% | Bullish | |
| $4.60 | $8.16 | $15.17 | +244% | Bullish | |
| $5.14 | $9.49 | $18.12 | +300% | Bullish | |
| $5.01 | $9.62 | $18.83 | +306% | Bullish | |
| $4.79 | $9.55 | $19.12 | +303% | Bullish | |
| $8.45 | $18.77 | $41.29 | +692% | Bullish | |
| $17.91 | $39.79 | $91.53 | +15.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.99 | $2.37 | $2.81 | +0.00% |
| June 2026 | $1.97 | $2.36 | $2.94 | -0.26% |
| July 2026 | $2.10 | $2.56 | $3.27 | +8.39% |
| August 2026 | $2.21 | $2.73 | $3.55 | +6.71% |
| September 2026 | $2.14 | $2.67 | $3.52 | -2.34% |
| October 2026 | $2.12 | $2.68 | $3.59 | +0.43% |
| November 2026 | $2.27 | $2.89 | $3.91 | +7.75% |
| December 2026 | $2.31 | $2.97 | $4.07 | +2.89% |
Click any year to see its month-by-month FATE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, FATE is projected to trade between $0.99 and $4.07, averaging $2.37 — a potential gain of 0% from today's $2.37. A consolidation phase looks the most probable path here.
Fate Therapeutics, Inc.'s 2027 outlook centres on $3.41, within a $2.46 to $5.13 range. That is up +44% on the projected 2026 average. That marks a +44% change versus current levels. Momentum favours further upside here.
By 2028, FATE could reach as high as $7.00, with a base case around $4.38 and support toward $2.97 — roughly +85% from $2.37. Buyers look set to stay in control over this stretch.
Expect FATE to range from $2.65 to $6.88 through 2029. The $4.11 average target implies a +73% move from current prices. That is -6% versus the projected 2028 average. Momentum favours further upside here.
The FATE price prediction for 2030 points to an average of $4.09 (low $2.51, high $7.13) — a potential gain of +72% on today's $2.37. Buyers look set to stay in control over this stretch.
In 2031, FATE is projected to trade between $3.53 and $10.82, averaging $6.00 — a potential gain of +153% from today's $2.37. That is up +47% on the projected 2030 average. Momentum favours further upside here.
Fate Therapeutics, Inc.'s 2032 outlook centres on $8.16, within a $4.60 to $15.17 range. That is up +36% on the projected 2031 average. That marks a +244% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, FATE could reach as high as $18.12, with a base case around $9.49 and support toward $5.14 — roughly +300% from $2.37. Momentum favours further upside here.
Expect FATE to range from $5.01 to $18.83 through 2034. The $9.62 average target implies a +306% move from current prices. That is up +1% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The FATE price prediction for 2035 points to an average of $9.55 (low $4.79, high $19.12) — a potential gain of +303% on today's $2.37. Momentum favours further upside here.
In 2040, FATE is projected to trade between $8.45 and $41.29, averaging $18.77 — a potential gain of +692% from today's $2.37. That is up +97% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Fate Therapeutics, Inc.'s 2050 outlook centres on $39.79, within a $17.91 to $91.53 range. That is up +112% on the projected 2040 average. That marks a +15.8x change versus current levels. Momentum favours further upside here.
Investing $1,000 in FATE today (≈ 421.940928 FATE) could be worth
$16,790.72
+$15,790.72 (+1579%) by 2050 · US Dollar
Based on the average projected FATE price of $39.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FATEwould be worth at today's price.
$1,000 invested in FATE on May 27, 2025 (≈ 819.672112 FATE) would be worth
$1,942.62
+$942.62 (+94.3%) today · 1.94× · US Dollar
Based on a FATE entry price of $1.22 vs. today's $2.37.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.84 | $1,288.04 | +28.8% |
| 1 month ago | $1.31 | $1,809.16 | +80.9% |
| 3 months ago | $1.56 | $1,519.23 | +51.9% |
| 6 months ago | $1.14 | $2,078.95 | +107.9% |
| 1 year ago | $1.22 | $1,942.62 | +94.3% |
| All time (5.0y) ago | $72.46 | $32.71 | -96.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FATE forecast.
Our base-case forecast reaches $4.70 around 2031.
Implied market cap at $4.70: $547.83M
The multi-year forecast shows a path of upside from 2026 onward. The 2026 min is $0.99, the avg is $2.25, and the max is $3.87, with an ROI of 0 and sentiment neutral.
From 2027 through 2030, the average prices rise from $3.25 to $3.78 while the max climbs to $6.60. ROI figures are 44.3 for 2027, 68.2 for 2030, with bullish sentiment across these years.
In the 2031–2035 window, the averages advance to $5.58, $7.39, $8.64, $8.86, and $8.59 respectively, with ROI numbers of 148, 228.6, 284.1, 293.6, and 281.7 and a continuing bullish outlook.
The forecast jumps significantly in 2040 and 2050, with an average of $16.91 and $34.59 and ROI of 651.5 and 1437.1 respectively, both labeled bullish. These figures imply substantial upside potential in the longer term, but these are estimates and not guarantees, and market dynamics can alter outcomes.
Tap a question to reveal the answer.
2030 avg $3.78; min $2.33; max $6.60; ROI 68.2; sentiment bullish.
The forecast includes bullish sentiment in 2027, 2028, 2029, 2031–2035 and beyond, with rising averages (e.g., $3.25 in 2027, $8.59 in 2035, $16.91 in 2040, $34.59 in 2050). 2026 is neutral. ROI figures rise over time, suggesting upside per the provided projections.
Yes. The 2031 max is $10.07, the 2032 max is $13.75, and the 2033 max is $16.51, indicating potential to exceed $10 in the forecast horizon.
Current price $2.25; Market cap $262.26M.
The 30-day technical picture is bullish. RSI14 is 60; SMA50 is $1.50 and SMA200 is $1.25. Support is $1.24 and resistance is $2.43. The 30-day range is $1.47 to $3.44.
Fate Therapeutics, Inc. Community Discussion
0Share your Fate Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.